Abstract
The treatment of advanced prostatic cancer is based upon the belief that this tumor is initially androgen dependent [1]. Therapeutic modalities therefore attempt to lower the level of circulating androgens. The two major clinical methods of achieving this aim are bilateral orchiectomy and the administration of pharmacologic doses of estrogens. While both techniques are effective in diminishing the level of circulating androgens and in inducing a remission in the majority of patients they both are associated with distinct clinical problems [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Huggins C, Hodges CV: Studies of prostatic cancer. I. The effect of castration, estrogen, and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293, 1941.
Walsh PC: Physiological basis for hormonal therapy in carcinoma of the prostate. In: The Prostate. Urol clin North Am. Philadelphia: Saunders WB, p 125, 1975.
Glashorn RW, Robinson MRG: Cardiovascular complications in the treatment of prostatic cancer. Br J Urol 53:624, 1981.
Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV: Structure of the porcine LH and FSH releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43:1334, 1971.
Sandow J, Von Rechenberg W, Jerzabek G, Engelbart K, Kuhl H, Fraser H: Hypothalamic pituitary testicular function in rats after supraphysiological doses of a highly active LRH analogue (Buserelin). Acta Endocrinol 94:489, 1980.
Trachtenberg J: Effect of chronic administration of potent luteinizing hormone releasing hormone analog on the rat prostate. J Urol 128:1097, 1982.
Tolis G, Mehta A, Kinch R, Comaru-Schally AM, Schally AV: Suppression of sex steroids by an LH-RH analogue in man. Clinical Res 28:676, 1980.
Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, Rabin D: Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in norman men. N Engl J Med 305:663, 1981.
Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM, Schally AV: Tumor growth inhibition in patients with prostatic cancer treated with luteinizing hormone releasing hormone agonists. Proc Natl Acad Sci USA 79:1658, 1982.
Trachtenberg J: The use of a potent luteinizing hormone releasing hormone analog agonist in the treatment of advanced prostatic cancer. J Urol (in press).
Trachtenberg J: A comparison of DES and a potent luteinizing hormone releasing hormone analog in the treatment of advanced prostatic cancer. In: Proceeding of the Annual Meeting of the American Urological Association. Abstract 34, 1983.
Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Husson JM: New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267, 1982.
Huggins C, Hodges CV: Studies of prostatic cancer. I. The effect of castration, estrogen, and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293, 1941.
Symes EK, Milroy E: An experimental approach to the optimum estrogen dosage in prostatic carcinoma. Br J Urol 50:562, 1978.
Byar DP: The Vetran’s Administration cooperative urological research group’s studies of cancer of the prostate. Cancer 32:116, 1973.
Alfthan O, Gholsti LR: Prevention of gynecomastia by local roentgen irradiation in estrogen treated prostatic cancer. Scand J Urol Nephrol 3:183, 1969.
Rivier C, Rivier J, Vale W: Chronic effects of [D-Trp6,Pro9-Net] luteinizing hormone releasing factor or reproductive processes in the male rat. Endocrinology 105:1191, 1979.
Labrie F, Cusan L, Sequin C, Belanger A, Pelletier G, Reves J, Kelly PA, Lemay A, Raynaud JP: Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int J Fertil 25:157, 1980.
Schmidt JD, Johnson DE, Scott WW, Gibbons RP, Prout GR, Murphy GP: Chemotherapy of advanced cancer. Evaluation of response parameters. Urology 7:602, 1976.
Walsh PC: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North A1 2:125, 1975.
Linde R, Doelle GC, Alexander N et al.: Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men. N Engl J Med 305:663, 1981.
Ellis WJ, Grayhack JT: Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 89:895, 1963.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Trachtenberg, J., Smith, J.A. (1984). Luteinizing Hormone Releasing Hormone Analog Agonists in the Treatment of Advanced Prostatic Cancer. In: Ratliff, T.L., Catalona, W.J. (eds) Urologic Oncology. Cancer Treatment and Research, vol 19. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2843-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2843-8_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9795-6
Online ISBN: 978-1-4613-2843-8
eBook Packages: Springer Book Archive